By April 15, 2009, the DDS shall complete a psychotropic medication review for all individuals served by DDS. By October 17, 2008, the DDS shall establish written procedures, which shall include timelines and shall identify responsible entities or individuals, for promptly implementing the recommendations for each individual identified by the psychotropic medication review. The psychotropic medication review shall be conducted by a review team that includes professionals with expertise in the prescription, use, and side effects of psychotropic medications as therapy for individuals who have been dually diagnosed with intellectual disabilities and mental illness. DDS shall establish in writing: Procedures for an initial administrative review of psychotropic medication prescriptions for all individuals served by DDS. Procedures and criteria for determining which individuals receive only an initial administrative review of psychotropic medications, and which individuals also receive a more detailed clinical review of psychotropic medications; and Criteria for screening and determining the clinical appropriateness of each psychotropic medication prescribed for each individual. The review team shall complete the initial administrative review of psychotropic medications. The initial administrative review of psychotropic medications shall determine, at minimum, for each individual served by DDS: All prescribed psychotropic medications; The diagnosis justifying each prescription; The provision of informed consent for each prescription; The presence of an accompanying behavioral plan; and Any other mental health services being provided to the individual. The review team shall conduct a clinical review of psychotropic medications when the initial administrative review meets the review team’s criteria indicating that a detailed clinical review of the individual’s psychotropic medication is warranted. The clinical review shall seek to determine the clinical appropriateness of each prescribed psychotropic medication and the potential for alternative approaches. The clinical review shall include, at a minimum, interviews with the individual, the prescribing professional, and the individual’s residential and day service providers, if any. By no later than 30 days after completing a psychotropic medication review of an individual, the review team shall issue a written report, which shall include recommendations for: Continued use, modification, or termination of psychotropic medication; Potential use of alternative approaches, including therapies, behavioral plans, skill development, and environmental modifications; Informed consent, if informed consent has not been provided; and Development of a behavioral plan, if no behavioral plan is present. A copy of the written report of the review team shall be appended to the individual’s individual habilitation plan and shall be provided to: The individual; The individual’s legal representative, if any; The individual’s advocate for a person with an intellectual disability, if any; The individual’s DDS case manager; Other persons identified in the individual’s individual habilitation plan as reasonably available, mentally capable, and willing to provide substituted consent pursuant to D.C. Official Code § 21-2210 , if any; The individual’s residential service provider; and The Quality Trust for Individuals with Disabilities, Inc.
‹ Prev All District Of Columbia sections Next ›
Lexace provides legal information, not legal advice, and no attorney–client relationship is created. Statute text is provided for general information and may not reflect the most recent amendments; verify against the official state code.